A Phase 1 Study of Surufatinib for Advanced Hepatocellular Carcinoma

Unknown Phase 2 NCT05282433

Study Description

A Study to Evaluate the Safety and Efficacy of Surufatinib Alone or Combined with Anti-PD-1 Antibody in Treating Advanced Liver and Pancreatic Cancers

Study Details

Registry ID:
NCT05282433
Conditions:
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
Phase:
Phase 2
Target Enrollment:
45 participants
Start Date:
Age Range:
18–75 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →